By Ilan Zipkin
Science Editor

As the U.S. government and NIH debate whether federal funding should be permitted for research involving the derivation or use of pluripotent human embryonic stem (ES) cells, academic researchers elsewhere in the world are finding fewer restrictions on their work. Thus academic research in the U.S. runs the risk of falling behind both privately funded interests and foreign academic competition with respect to therapeutic applications of human ES cells.